Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
- 72k Downloads
To provide an update to the original Surviving Sepsis Campaign clinical management guidelines, “Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock,” published in 2004.
Modified Delphi method with a consensus conference of 55 international experts, several subsequent meetings of subgroups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. This process was conducted independently of any industry funding.
We used the GRADE system to guide assessment of quality of evidence from high (A) to very low (D) and to determine the strength of recommendations. A strong recommendation  indicates that an intervention's desirable effects clearly outweigh its undesirable effects (risk, burden, cost), or clearly do not. Weak recommendations  indicate that the tradeoff between desirable and undesirable effects is less clear. The grade of strong or weak is considered of greater clinical importance than a difference in letter level of quality of evidence. In areas without complete agreement, a formal process of resolution was developed and applied. Recommendations are grouped into those directly targeting severe sepsis, recommendations targeting general care of the critically ill patient that are considered high priority in severe sepsis, and pediatric considerations.
Key recommendations, listed by category, include: early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition (1C); blood cultures prior to antibiotic therapy (1C); imaging studies performed promptly to confirm potential source of infection (1C); administration of broad-spectrum antibiotic therapy within 1 hr of diagnosis of septic shock (1B) and severe sepsis without septic shock (1D); reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate (1C); a usual 7–10 days of antibiotic therapy guided by clinical response (1D); source control with attention to the balance of risks and benefits of the chosen method (1C); administration of either crystalloid or colloid fluid resuscitation (1B); fluid challenge to restore mean circulating filling pressure (1C); reduction in rate of fluid administration with rising filing pressures and no improvement in tissue perfusion (1D); vasopressor preference for norepinephrine or dopamine to maintain an initial target of mean arterial pressure ≥ 65 mm Hg (1C); dobutamine inotropic therapy when cardiac output remains low despite fluid resuscitation and combined inotropic/vasopressor therapy (1C); stress-dose steroid therapy given only in septic shock after blood pressure is identified to be poorly responsive to fluid and vasopressor therapy (2C); recombinant activated protein C in patients with severe sepsis and clinical assessment of high risk for death (2B except 2C for post-operative patients). In the absence of tissue hypoperfusion, coronary artery disease, or acute hemorrhage, target a hemoglobin of 7–9 g/dL (1B); a low tidal volume (1B) and limitation of inspiratory plateau pressure strategy (1C) for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS); application of at least a minimal amount of positive end-expiratory pressure in acute lung injury (1C); head of bed elevation in mechanically ventilated patients unless contraindicated (1B); avoiding routine use of pulmonary artery catheters in ALI/ARDS (1A); to decrease days of mechanical ventilation and ICU length of stay, a conservative fluid strategy for patients with established ALI/ARDS who are not in shock (1C); protocols for weaning and sedation/analgesia (1B); using either intermittent bolus sedation or continuous infusion sedation with daily interruptions or lightening (1B); avoidance of neuromuscular blockers, if at all possible (1B); institution of glycemic control (1B) targeting a blood glucose < 150 mg/dL after initial stabilization ( 2C ); equivalency of continuous veno-veno hemofiltration or intermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1A); use of stress ulcer prophylaxis to prevent upper GI bleeding using H2 blockers (1A) or proton pump inhibitors (1B); and consideration of limitation of support where appropriate (1D).
Recommendations specific to pediatric severe sepsis include: greater use of physical examination therapeutic end points (2C); dopamine as the first drug of choice for hypotension (2C); steroids only in children with suspected or proven adrenal insufficiency (2C); a recommendation against the use of recombinant activated protein C in children (1B).
There was strong agreement among a large cohort of international experts regarding many level 1 recommendations for the best current care of patients with severe sepsis. Evidenced-based recommendations regarding the acute management of sepsis and septic shock are the first step toward improved outcomes for this important group of critically ill patients.
KeywordsSepsis Severe sepsis Septic shock Sepsis syndrome Infection GRADE Guidelines Evidence-based medicine Surviving Sepsis Campaign Sepsis bundles
Severe sepsis (acute organ dysfunction secondary to infection) and septic shock (severe sepsis plus hypotension not reversed with fluid resuscitation) are major healthcare problems, affecting millions of individuals around the world each year, killing one in four (and often more), and increasing in incidence [1, 2, 3, 4, 5]. Similar to polytrauma, acute myocardial infarction, or stroke, the speed and appropriateness of therapy administered in the initial hours after severe sepsis develops are likely to influence outcome. In 2004, an international group of experts in the diagnosis and management of infection and sepsis, representing 11 organizations, published the first internationally accepted guidelines that the bedside clinician could use to improve outcomes in severe sepsis and septic shock [6, 7]. These guidelines represented Phase II of the Surviving Sepsis Campaign (SSC), an international effort to increase awareness and improve outcomes in severe sepsis. Joined by additional organizations, the group met again in 2006 and 2007 to update the guidelines document using a new evidence-based methodology system for assessing quality of evidence and strength of recommendations [8, 9, 10, 11].
These recommendations are intended to provide guidance for the clinician caring for a patient with severe sepsis or septic shock. Recommendations from these guidelines cannot replace the clinician's decision-making capability when he or she is provided with a patient's unique set of clinical variables. Most of these recommendations are appropriate for the severe sepsis patient in both the intensive care unit (ICU) and non-ICU settings. In fact the committee believes that, currently, the greatest outcome improvement can be made through education and process change for those caring for severe sepsis patients in the non-ICU setting and across the spectrum of acute care. It should also be noted that resource limitations in some institutions and countries may prevent physicians from accomplishing particular recommendations.
Determination of the Quality of Evidence
• Underlying methodology
Downgraded RCT or upgraded observational studies
Well-done observational studies
Case series or expert opinion
• Factors that may decrease the strength of evidence
Poor quality of planning and implementation of available RCTs suggesting high likelihood of bias
Inconsistency of results (including problems with subgroup analyses)
Indirectness of evidence (differing population, intervention, control, outcomes, comparison)
Imprecision of results
High likelihood of reporting bias
• Main factors that may increase the strength of evidence
Large magnitude of effect (direct evidence, relative risk (RR) > 2 with no plausible confounders)
Very large magnitude of effect with RR > 5 and no threats to validity (by two levels)
Dose response gradient
Factors Determining Strong vs. Weak Recommendation
What should be considered
Quality of evidence
The lower the quality of evidence the less likely a strong recommendation
Relative importance of the outcomes
If values and preferences vary widely, a strong recommendation becomes less likely
Baseline risks of outcomes
The higher the risk, the greater the magnitude of benefit
Magnitude of relative risk including benefits, harms, and burden
Larger relative risk reductions or larger increases in relative risk of harm make a strong recommendation more or less likely respectively
Absolute magnitude of the effect
The larger the absolute benefits and harms, the greater or lesser likelihood respectively of a strong recommendation
Precision of the estimates of the effects
The greater the precision the more likely is a strong recommendation
The higher the cost of treatment, the less likely a strong recommendation
The current clinical practice guidelines build on the first and second editions from 2001 (see below) and 2004 [6, 7, 14]. The 2001 publication incorporated a MEDLINE search for clinical trials in the preceding 10 years, supplemented by a manual search of other relevant journals . The 2004 publication incorporated the evidence available through the end of 2003. The current publication is based on an updated search into 2007 (see methods and rules below).
The 2001 guidelines were coordinated by the International Sepsis Forum (ISF); the 2004 guidelines were funded by unrestricted educational grants from industry and administered through the Society of Critical Care Medicine (SCCM), the European Society of Intensive Care Medicine (ESICM), and ISF. Two of the SSC administering organizations receive unrestricted industry funding to support SSC activities (ESICM and SCCM), but none of this funding was used to support the 2006–2007 committee meetings.
It is important to distinguish between the process of guidelines revision and the Surviving Sepsis Campaign. The Surviving Sepsis Campaign (SSC) is partially funded by unrestricted educational industry grants, including those from Edwards LifeSciences, Eli Lilly and Company, and Philips Medical Systems. SSC also received funding from the Coalition for Critical Care Excellence of the Society of Critical Care Medicine. The great majority of industry funding has come from Eli Lilly and Company.
Current industry funding for the Surviving Sepsis Campaign is directed to the performance improvement initiative. No industry funding was used in the guidelines revision process.
For both the 2004 and the 2006/2007 efforts there were no members of the committee from industry, no industry input into guidelines development, and no industry presence at any of the meetings. Industry awareness or comment on the recommendations was not allowed. No member of the guideline committee received any honoraria for any role in the 2004 or 2006/2007 guidelines process. The committee considered the issue of recusement of individual committee members during deliberation and decision making in areas where committee members had either financial or academic competing interests; however, consensus as to threshold for exclusion could not be reached. Alternatively, the committee agreed to ensure full disclosure and transparency of all committee members' potential conflicts at time of publication (see disclosures at the end of this document).
The guidelines process included a modified Delphi method, a consensus conference, several subsequent meetings of subgroups and key individuals, teleconferences and electronically based discussions among subgroups and members of the entire committee and two follow-up nominal group meetings in 2007.
Subgroups were formed, each charged with updating recommendations in specific areas, including corticosteroids, blood products, activated protein C, renal replacement therapy, antibiotics, source control, and glucose control, etc. Each subgroup was responsible for updating the evidence (into 2007, with major additional elements of information incorporated into the evolving manuscript throughout 2006 and 2007). A separate search was performed for each clearly defined question. The committee chair worked with subgroup heads to identify pertinent search terms that always included, at a minimum, sepsis, severe sepsis, septic shock and sepsis syndrome crossed against the general topic area of the subgroup as well as pertinent key words of the specific question posed. All questions of the previous guidelines publications were searched, as were pertinent new questions generated by general topic related search or recent trials. Quality of evidence was judged by pre-defined Grades of Recommendation, Assessment, Development and Evaluation (GRADE) criteria (see below). Significant education of committee members on the GRADE approach was performed via email prior to the first committee meeting and at the first meeting. Rules were distributed concerning assessing the body of evidence and GRADE experts were available for questions throughout the process. Subgroups agreed electronically on draft proposals that were presented to committee meetings for general discussion. In January 2006, the entire group met during the 35th SCCM Critical Care Congress in San Francisco, California, USA. The results of that discussion were incorporated into the next version of recommendations and again discussed using electronic mail. Recommendations were finalized during nominal group meetings (composed of a subset of the committee members) at the 2007 SCCM (Orlando) and 2007 International Symposium on Intensive Care and Emergency Medicine (Brussels) meetings with recirculation of deliberations and decisions to the entire group for comment or approval. At the discretion of the chair and following adequate discussion, competing proposals for wording of recommendations or assigning strength of evidence were resolved by formal voting. On occasions, voting was performed to give the committee a sense of distribution of opinions to facilitate additional discussion. The manuscript was edited for style and form by the writing committee with final approval by section leads for their respective group assignment and then by the entire committee.
The development of guidelines and grading of recommendations for the 2004 guideline development process were based on a system proposed by Sackett in 1989, during one of the first American College of Chest Physicians (ACCP) conferences on the use of antithrombotic therapies . The revised guidelines recommendations are based on the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) system – a structured system for rating quality of evidence and grading strength of recommendation in clinical practice [8, 9, 10, 11]. The SSC Steering Committee and individual authors collaborated with GRADE representatives to apply the GRADE system to the SSC guidelines revision process. The members of GRADE group were directly involved, either in person or via e-mail, in all discussions and deliberations amongst the guidelines committee members as to grading decisions. Subsequently, the SSC authors used written material prepared by the GRADE group and conferred with GRADE group members who were available at the first committee meeting and subsequent nominal group meetings. GRADE representatives were also used as a resource throughout subgroup deliberation.
The GRADE system is based on a sequential assessment of the quality of evidence, followed by assessment of the balance between benefits versus risks, burden, and cost and, based on the above, development and grading of a management recommendations [9, 10, 11]. Keeping the rating of quality of evidence and strength of recommendation explicitly separate constitutes a crucial and defining feature of the GRADE approach. This system classifies quality of evidence as high (Grade A), moderate (Grade B), low (Grade C), or very low (Grade D). Randomized trials begin as high quality evidence, but may be downgraded due to limitations in implementation, inconsistency or imprecision of the results, indirectness of the evidence, and possible reporting bias (see Table 1). Examples of indirectness of the evidence include: population studied, interventions used, outcomes measured, and how these relate to the question of interest. Observational (non-randomized) studies begin as low-quality evidence, but the quality level may be upgraded on the basis of large magnitude of effect. An example of this is the quality of evidence for early administration of antibiotics.
The GRADE system classifies recommendations as strong (Grade 1) or weak (Grade 2). The grade of strong or weak is considered of greater clinical importance than a difference in letter level of quality of evidence. The committee assessed whether the desirable effects of adherence will outweigh the undesirable effects, and the strength of a recommendation reflects the group's degree of confidence in that assessment. A strong recommendation in favor of an intervention reflects that the desirable effects of adherence to a recommendation (beneficial health outcomes, less burden on staff and patients, and cost savings) will clearly outweigh the undesirable effects (harms, more burden and greater costs). A weak recommendation in favor of an intervention indicates that the desirable effects of adherence to a recommendation probably will outweigh the undesirable effects, but the panel is not confident about these tradeoffs – either because some of the evidence is low-quality (and thus there remains uncertainty regarding the benefits and risks) or the benefits and downsides are closely balanced. While the degree of confidence is a continuum and there is a lack of a precise threshold between a strong and a weak recommendation, the presence of important concerns about one or more of the above factors makes a weak recommendation more likely. A “strong” recommendation is worded as “we recommend” and a weak recommendation as “we suggest.”
The implications of calling a recommendation “strong” are that most well-informed patients would accept that intervention, and that most clinicians should use it in most situations. There may be circumstances in which a “strong” recommendation cannot or should not be followed for an individual patient because of that patient's preferences or clinical characteristics which make the recommendation less applicable. It should be noted that being a “strong” recommendation does not automatically imply standard of care. For example, the strong recommendation for administering antibiotics within one hour of the diagnosis of severe sepsis, although desirable, is not currently standard of care as verified by current practice (personal communication, Mitchell Levy from first 8,000 patients entered internationally into the SSC performance improvement data base). The implication of a “weak” recommendation is that although a majority of well-informed patients would accept it (but a substantial proportion would not), clinicians should consider its use according to particular circumstance.
Differences of opinion among committee members about interpretation of evidence, wording of proposals, or strength of recommendations were resolved using a specifically developed set of rules. We will describe this process in detail in a separate publication. In summary, the main approach for converting diverse opinions into a recommendation was: 1. to give a recommendation a direction (for or against the given action). a majority of votes were to be in favor of that direction, with no more than 20% preferring the opposite direction (there was a neutral vote allowed as well); 2. to call a given recommendation “strong” rather than “weak” at least 70% “strong” votes were required; 3. if fewer than 70% of votes indicated “strong” preference, the recommendation was assigned a “weak” category of strength. We used a combination of modified Delphi Process and Nominal (Expert) Group techniques to ensure both depth and breadth of review. The entire review group (together with their parent organizations as required) participated in the larger, iterative, modified Delphi process. The smaller working group meetings which took place in person functioned as the Nominal Groups. If a clear consensus could not be obtained by polling within the Nominal Group meetings, the larger group was specifically asked to use the polling process. This was only required for corticosteroids and glycemic control. The larger group had the opportunity to review all outputs. In this way the entire review combined intense focused discussion (Nominal Group) with broader review and monitoring using the Delphi process.
Initial Resuscitation and Infection Issues
Initial resuscitation (first 6 hours)
Strength of recommendation and quality of evidence have been assessed using the GRADE criteria, presented in brackets after each guideline. For added clarity: • Indicates a strong recommendation or “we recommend”; ○ indicates a weak recommendation or “we suggest”
• Begin resuscitation immediately in patients with hypotension or elevated serum lactate > 4mmol/l; do not delay pending ICU admission.(1C)
• Resuscitation goals:(1C)
– Central venous pressure (CVP) 8–12 mm Hg*
– Mean arterial pressure ≥ 65 mm Hg
– Urine output ≥ 0.5 mL.kg-1.hr-1
– Central venous (superior vena cava) oxygen saturation ≥ 70%, or mixed venous ≥ 65%
○ If venous O2 saturation target not achieved: (2C)
– consider further fluid
– transfuse packed red blood cells if required to hematocrit of ≥ 30% and/or
– dobutamine infusion max 20 μg.kg-1.min-1
* A higher target CVP of 12–15 mm Hg is recommended in the presence of mechanical ventilation or pre-existing decreased ventricular compliance.
• Obtain appropriate cultures before starting antibiotics provided this does not significantly delay antimicrobial administration.(1C)
– Obtain two or more blood cultures (BCs)
– One or more BCs should be percutaneous
– One BC from each vascular access device in place > 48 h
– Culture other sites as clinically indicated
• Perform imaging studies promptly in order to confirm and sample any source of infection; if safe to do so.(1C)
• Begin intravenous antibiotics as early as possible, and always within the first hour of recognizing severe sepsis (1D) and septic shock (1B).
• Broad-spectrum: one or more agents active against likely bacterial/fungal pathogens and with good penetration into presumed source.(1B)
• Reassess antimicrobial regimen daily to optimise efficacy, prevent resistance, avoid toxicity & minimise costs.(1C)
○ Consider combination therapy in Pseudomonas infections.(2D)
○ Consider combination empiric therapy in neutropenic patients.(2D)
○ Combination therapy no more than 3–5 days and deescalation following susceptibilities.(2D)
• Duration of therapy typically limited to 7–10 days; longer if response slow, undrainable foci of infection, or immunologic deficiencies.(1D)
• Stop antimicrobial therapy if cause is found to be non-infectious.(1D)
Source identification and control
• A specific anatomic site of infection should be established as rapidly as possible(1C) and within first 6 hrs of presentation(1D).
• Formally evaluate patient for a focus of infection amenable to source control measures (eg: abscess drainage, tissue debridement).(1C)
• Implement source control measures as soon as possible following successful initial resuscitation.(1C)
Exception: infected pancreatic necrosis, where surgical intervention best delayed. (2B)
• Choose source control measure with maximum efficacy and minimal physiologic upset.(1D)
• Remove intravascular access devices if potentially infected.(1C)
Hemodynamic Support and Adjunctive Therapy
Strength of recommendation and quality of evidence have been assessed using the GRADE criteria, presented in brackets after each guideline. For added clarity: • Indicates a strong recommendation or “we recommend”; ○ indicates a weak recommendation or “we suggest”
• Fluid-resuscitate using crystalloids or colloids.(1B)
• Target a CVP of ≥ 8 mm Hg (≥ 12 mm Hg if mechanically ventilated).(1C)
• Use a fluid challenge technique while associated with a haemodynamic improvement.(1D)
• Give fluid challenges of 1000 ml of crystalloids or 300–500 ml of colloids over 30 min. More rapid and larger volumes may be required in sepsis-induced tissue hypoperfusion.(1D)
• Rate of fluid administration should be reduced if cardiac filling pressures increase without concurrent hemodynamic improvement.(1D)
• Maintain MAP ≥ 65 mm Hg.(1C)
• Norepinephrine or dopamine centrally administered are the initial vasopressors of choice.(1C)
○ Epinephrine, phenylephrine or vasopressin should not be administered as the initial vasopressor in septic shock.(2C)
– Vasopressin 0.03 units/min maybe subsequently added to norepinephrine with anticipation of an effect equivalent to norepinephrine alone.
○ Use epinephrine as the first alternative agent in septic shock when blood pressure is poorly responsive to norepinephrine or dopamine.(2B)
• Do not use low-dose dopamine for renal protection.(1A)
• In patients requiring vasopressors, insert an arterial catheter as soon as practical.(1D)
• Use dobutamine in patients with myocardial dysfunction as supported by elevated cardiac filling pressures and low cardiac output.(1C)
• Do not increase cardiac index to predetermined supranormal levels.(1B)
○ Consider intravenous hydrocortisone for adult septic shock when hypotension remains poorly responsive to adequate fluid resuscitation and vasopressors.(2C)
○ ACTH stimulation test is not recommended to identify the subset of adults with septic shock who should receive hydrocortisone.(2B)
○ Hydrocortisone is preferred to dexamethasone.(2B)
○ Fludrocortisone (50 μg orally once a day) may be included if an alternative to hydrocortisone is being used which lacks significant mineralocorticoid activity. Fludrocortisone is optional if hydrocortisone is used.(2C)
○ Steroid therapy may be weaned once vasopressors are no longer required.(2D)
• Hydrocortisone dose should be < 300 mg/day.(1A)
• Do not use corticosteroids to treat sepsis in the absence of shock unless the patient's endocrine or corticosteroid history warrants it.(1D)
Recombinant human activated protein C (rhAPC)
○ Consider rhAPC in adult patients with sepsis-induced organ dysfunction with clinical assessment of high risk of death (typically APACHE II ≥ 25 or multiple organ failure) if there are no contraindications.(2B,2Cforpost-operativepatients)
• Adult patients with severe sepsis and low risk of death (eg: APACHE II<20 or one organ failure) should not receive rhAPC.(1A)
Other Supportive Therapy of Severe Sepsis
Blood product administration
Strength of recommendation and quality of evidence have been assessed using the GRADE criteria, presented in brackets after each guideline. For added clarity: • Indicates a strong recommendation or “we recommend”; ○ indicates a weak recommendation or “we suggest”
• Give red blood cells when hemoglobin decreases to < 7.0 g/dl (< 70 g/L) to target a hemoglobin of 7.0–9.0 g/dl in adults.(1B)
– A higher hemoglobin level may be required in special circumstances (e. g.: myocardial ischaemia, severe hypoxemia, acute haemorrhage, cyanotic heart disease or lactic acidosis)
• Do not use erythropoietin to treat sepsis-related anemia. Erythropoietin may be used for other accepted reasons.(1B)
• Do not use fresh frozen plasma to correct laboratory clotting abnormalities unless there is bleeding or planned invasive procedures.(2D)
○ Do not use antithrombin therapy.(1B)
• Administer platelets when: (2D)
– counts are < 5000/mm3 (5 × 109/L) regardless of bleeding.
– counts are 5000 to 30,000/mm3 (5–30 × 109/L) and there is significant bleeding risk.
– Higher platelet counts (≥ 50,000/mm3 (50 × 109/L)) are required for surgery or invasive procedures.
Mechanical ventilation of sepsis-induced acute lung injury (ALI)/ARDS
• Target a tidal volume of 6 ml/kg (predicted) body weight in patients with ALI/ARDS.(1B)
• Target an initial upper limit plateau pressure < 30 cm H2O. Consider chest wall compliance when assessing plateau pressure.(1C)
• Allow PaCO2 to increase above normal, if needed to minimize plateau pressures and tidal volumes.(1C)
• Positive end expiratory pressure (PEEP) should be set to avoid extensive lung collapse at end expiration.(1C)
○ Consider using the prone position for ARDS patients requiring potentially injurious levels of FiO2 or plateau pressure, provided they are not put at risk from positional changes.(2C)
• Maintain mechanically ventilated patients in a semi-recumbent position (head of the bed raised to 45 °) unless contraindicated(1B), between 30 –45 (2C).
○ Non invasive ventilation may be considered in the minority of ALI/ARDS patients with mild-moderate hypoxemic respiratory failure. The patients need to be hemodynamically stable, comfortable, easily arousable, able to protect/clear their airway and expected to recover rapidly.(2B)
• Use a weaning protocol and a spontaneous breathing trial (SBT) regularly to evaluate the potential for discontinuing mechanical ventilation.(1A)
– SBT options include a low level of pressure support with continuous positive airway pressure 5 cm H2O or a T-piece.
– Before the SBT, patients should:
– be arousable
– be haemodynamically stable without vasopressors
– have no new potentially serious conditions
– have low ventilatory and end-expiratory pressure requirement
– require FiO2 levels that can be safely delivered with a face mask or nasal cannula
• Do not use a pulmonary artery catheter for the routine monitoring of patients with ALI/ARDS.(1A)
• Use a conservative fluid strategy for patients with established ALI who do not have evidence of tissue hypoperfusion.(1C)
Sedation, analgesia, and neuromuscular blockade in sepsis
• Use sedation protocols with a sedation goal for critically ill mechanically ventilated patients.(1B)
• Use either intermittent bolus sedation or continuous infusion sedation to predetermined end points (sedation scales), with daily interruption/lightening to produce awakening. Re-titrate if necessary.(1B)
• Avoid neuromuscular blockers (NMBs) where possible. Monitor depth of block with train of four when using continuous infusions.(1B)
• Use IV insulin to control hyperglycemia in patients with severe sepsis following stabilization in the ICU.(1B)
• Aim to keep blood glucose < 150 mg/dl (8.3 mmol/L) using a validated protocol for insulin dose adjustment.(2C)
• Provide a glucose calorie source and monitor blood glucose values every 1–2 hrs (4 hrs when stable) in patients receiving intravenous insulin.(1C)
• Interpret with caution low glucose levels obtained with point of care testing, as these techniques may overestimate arterial blood or plasma glucose values.(1B)
○ Intermittent hemodialysis and continuous veno-venous haemofiltration (CVVH) are considered equivalent.(2B)
○ CVVH offers easier management in hemodynamically unstable patients.(2D)
• Do not use bicarbonate therapy for the purpose of improving hemodynamics or reducing vasopressor requirements when treating hypoperfusion-induced lactic acidemia with pH ≥ 7.15.(1B)
Deep vein thrombosis (DVT) prophylaxis
• Use either low-dose unfractionated heparin (UFH) or low-molecular weight heparin (LMWH), unless contraindicated.(1A)
• Use a mechanical prophylactic device, such as compression stockings or an intermittent compression device, when heparin is contraindicated.(1A)
○ Use a combination of pharmacologic and mechanical therapy for patients who are at very high risk for DVT.(2C)
○ In patients at very high risk LMWH should be used rather than UFH.(2C)
Stress ulcer prophylaxis
• Provide stress ulcer prophylaxis using H2 blocker(1A) or proton pump inhibitor(1B). Benefits of prevention of upper GI bleed must be weighed against the potential for development of ventilator-associated pneumonia.
Consideration for limitation of support
• Discuss advance care planning with patients and families. Describe likely outcomes and set realistic expectations.(1D)
I. Management of Severe Sepsis
A. Initial Resuscitation
- 1.We recommend the protocolized resuscitation of a patient with sepsis-induced shock, defined as tissue hypoperfusion (hypotension persisting after initial fluid challenge or blood lactate concentration equal to or greater than 4 mmol/L). This protocol should be initiated as soon as hypoperfusion is recognized and should not be delayed pending ICU admission. During the first 6 hrs of resuscitation, the goals of initial resuscitation of sepsis-induced hypoperfusion should include all of the following as one part of a treatment protocol:
Central venous pressure (CVP): 8–12 mm Hg
Mean arterial pressure (MAP) ≥ 65 mm Hg
Urine output ≥ 0.5 mL.kg−1.hr −1
Central venous (superior vena cava) or mixed venous oxygen saturation ≥ 70% or ≥ 65%, respectively (Grade 1C)
There are recognized limitations to ventricular filling pressure estimates as surrogates for fluid resuscitation [28, 29]. However, measurement of CVP is currently the most readily obtainable target for fluid resuscitation. There may be advantages to targeting fluid resuscitation to flow and perhaps to volumetric indices (and even to microcirculation changes) [30, 31, 32, 33]. Technologies currently exist that allow measurement of flow at the bedside [34, 35]. Future goals should be making these technologies more accessible during the critical early resuscitation period and research to validate utility. These technologies are already available for early ICU resuscitation.
We suggest that during the first 6 hrs of resuscitation of severe sepsis or septic shock, if SCVO2 or SvO2 of 70% or 65% respectively is not achieved with fluid resuscitation to the CVP target, then transfusion of packed red blood cells to achieve a hematocrit of ≥ 30% and/or administration of a dobutamine infusion (up to a maximum of 20 μg.kg−1.min−1) be utilized to achieve this goal (Grade 2C).
We recommend obtaining appropriate cultures before antimicrobial therapy is initiated if such cultures do not cause significant delay in antibiotic administration. To optimize identification of causative organisms, we recommend at least two blood cultures be obtained prior to antibiotics with at least one drawn percutaneously and one drawn through each vascular access device, unless the device was recently (< 48 h) inserted. Cultures of other sites (preferably quantitative where appropriate) such as urine, cerebrospinal fluid, wounds, respiratory secretions, or other body fluids that may be the source of infection should also be obtained before antibiotic therapy if not associated with significant delay in antibiotic administration (Grade 1C).
We recommend that imaging studies be performed promptly in attempts to confirm a potential source of infection. Sampling of potential sources of infection should occur as they are identified; however, some patients may be too unstable to warrant certain invasive procedures or transport outside of the ICU. Bedside studies, such as ultrasound, are useful in these circumstances (Grade 1C).
C. Antibiotic Therapy
We recommend that intravenous antibiotic therapy be started as early as possible and within the first hour of recognition of septic shock (1B) and severe sepsis without septic shock (1D). Appropriate cultures should be obtained before initiating antibiotic therapy, but should not prevent prompt administration of antimicrobial therapy (Grade 1D).
We recommend that initial empirical anti-infective therapy include one or more drugs that have activity against all likely pathogens (bacterial and/or fungal) and that penetrate in adequate concentrations into the presumed source of sepsis (Grade 1B).
Recently used antibiotics should generally be avoided. Clinicians should be cognizant of the virulence and growing prevalence of oxacillin (methicillin) resistant Staphylococcus aureus (ORSA or MRSA) in some communities and healthcare associated settings (especially in the United States) when they choose empiric therapy. If the prevalence is significant, and in consideration of the virulence of this organism, empiric therapy adequate for this pathogen would be warranted. Clinicians should also consider whether Candidemia is a likely pathogen when choosing initial therapy. When deemed warranted, the selection of empiric antifungal therapy (e. g., fluconazole, amphotericin B, or echinocandin) will be tailored to the local pattern of the most prevalent Candida species, and any prior administration of azoles drugs . Risk factors for candidemia should also be considered when choosing initial therapy.
Because patients with severe sepsis or septic shock have little margin for error in the choice of therapy, the initial selection of antimicrobial therapy should be broad enough to cover all likely pathogens. There is ample evidence that failure to initiate appropriate therapy (i. e. therapy with activity against the pathogen that is subsequently identified as the causative agent) correlates with increased morbidity and mortality [45, 46, 47, 48].
Patients with severe sepsis or septic shock warrant broad-spectrum therapy until the causative organism and its antibiotic susceptibilities are defined. Restriction of antibiotics as a strategy to reduce the development of antimicrobial resistance or to reduce cost is not an appropriate initial strategy in this patient population.
All patients should receive a full loading dose of each antimicrobial. However, patients with sepsis or septic shock often have abnormal renal or hepatic function and may have abnormal volumes of distribution due to aggressive fluid resuscitation. Drug serum concentration monitoring can be useful in an ICU setting for those drugs that can be measured promptly. An experienced physician or clinical pharmacist should be consulted to ensure that serum concentrations are attained that maximize efficacy and minimize toxicity [49, 50, 51, 52].
We recommend that the antimicrobial regimen be reassessed daily to optimize activity, to prevent the development of resistance, to reduce toxicity, and to reduce costs (Grade 1C).
Narrowing the spectrum of antibiotic coverage and reducing the duration of antibiotic therapy will reduce the likelihood that the patient will develop superinfection with pathogenic or resistant organisms such as Candida species, Clostridium difficile, or vancomycin-resistant Enterococcus faecium. However, the desire to minimize superinfections and other complications should not take precedence over the need to give the patient an adequate course of therapy to cure the infection that caused the severe sepsis or septic shock.
We suggest combination therapy for patients with known or suspected Pseudomonas infections as a cause of severe sepsis (Grade 2D).
We suggest combination empiric therapy for neutropenic patients with severe sepsis (Grade 2D).
When used empirically in patients with severe sepsis, we suggest that combination therapy should not be administered for more than 3 to 5 days. De-escalation to the most appropriate single therapy should be performed as soon as the susceptibility profile is known. (Grade 2D).
We recommend that the duration of therapy typically be 7–10 days; longer courses may be appropriate in patients who have a slow clinical response, undrainable foci of infection, or who have immunologic deficiencies including neutropenia (Grade 1D).
If the presenting clinical syndrome is determined to be due to a noninfectious cause, we recommend antimicrobial therapy be stopped promptly to minimize the likelihood that the patient will become infected with an antibiotic resistant pathogen or will develop a drug related adverse effect (Grade 1D).
D. Source Control
We recommend that a specific anatomic diagnosis of infection requiring consideration for emergent source control- for example necrotizing fasciitis, diffuse peritonitis, cholangitis, intestinal infarction – be sought and diagnosed or excluded as rapidly as possible (Grade 1C) and within the first 6 hours following presentation (Grade 1D).
We further recommend that all patients presenting with severe sepsis be evaluated for the presence of a focus of infection amenable to source control measures, specifically the drainage of an abscess or local focus of infection, the debridement of infected necrotic tissue, the removal of a potentially infected device, or the definitive control of a source of ongoing microbial contamination (Grade 1C) (see Appendix A for examples of potential sites needing source control).
We suggest that when infected peripancreatic necrosis is identified as a potential source of infection, definitive intervention is best delayed until adequate demarcation of viable and non-viable tissues has occurred (Grade 2B).
We recommend that when source control is required, the effective intervention associated with the least physiologic insult be employed e. g., percutaneous rather than surgical drainage of an abscess (Grade 1D).
We recommend that when intravascular access devices are a possible source of severe sepsis or septic shock, they be promptly removed after establishing other vascular access (Grade 1C).
E. Fluid Therapy
We recommend fluid resuscitation with either natural/artificial colloids or crystalloids. There is no evidence-based support for one type of fluid over another (Grade 1B).
We recommend fluid resuscitation initially target a CVP of at least 8 mm Hg (12 mm Hg in mechanically ventilated patients). Further fluid therapy is often required (Grade 1C).
We recommend that a fluid challenge technique be applied, wherein fluid administration is continued as long as the hemodynamic improvement (e. g., arterial pressure, heart rate, urine output) continues (Grade 1D).
We recommend fluid challenge in patients with suspected hypovolemia be started with at least 1000 mL of crystalloids or 300–500 mL of colloids over 30 min. More rapid administration and greater amounts of fluid may be needed in patients with sepsis induced tissue hypoperfusion (see initial resuscitation recommendations) (Grade 1D).
We recommend the rate of fluid administration be reduced substantially when cardiac filling pressures (CVP or pulmonary artery balloon-occluded pressure) increase without concurrent hemodynamic improvement (Grade 1D).
We recommend mean arterial pressure (MAP) be maintained ≥ 65 mm Hg (Grade 1C).
We recommend either norepinephrine or dopamine as the first choice vasopressor agent to correct hypotension in septic shock (administered through a central catheter as soon as one is available) (Grade 1C).
We suggest that epinephrine, phenylephrine, or vasopressin should not be administered as the initial vasopressor in septic shock (Grade 2C). Vasopressin .03 units/min may be subsequently added to norepinephrine with anticipation of an effect equivalent to norepinephrine alone.
We suggest that epinephrine be the first chosen alternative agent in septic shock that is poorly responsive to norepinephrine or dopamine (Grade 2B).
Vasopressin levels in septic shock have been reported to be lower than anticipated for a shock state . Low doses of vasopressin may be effective in raising blood pressure in patients refractory to other vasopressors, and may have other potential physiologic benefits [88, 89, 90, 91, 92, 93]. Terlipressin has similar effects but is long lasting . Studies show that vasopressin concentrations are elevated in early septic shock, but with continued shock, concentration decreases to normal range in the majority of patients between 24 and 48 hrs . This has been called “relative vasopressin deficiency” because in the presence of hypotension, vasopressin would be expected to be elevated. The significance of this finding is unknown. The recent VASST trial, a randomized, controlled trial comparing norepinephrine alone to norepinephrine plus vasopressin at .03 units per minute showed no difference in outcome in the intent to treat population. An a priori defined subgroup analysis showed that the survival of patients receiving less than 15 μg/min norepinephrine at the time of randomization was better with vasopressin. It should be noted however that the pre-trial rationale for this stratification was based on exploring potential benefit in the 15 μg or greater norepinephrine requirement population. Higher doses of vasopressin have been associated with cardiac, digital, and splanchnic ischemia and should be reserved for situations where alternative vasopressors have failed . Cardiac output measurement to allow maintenance of a normal or elevated flow is desirable when these pure vasopressors are instituted.
We recommend that low dose dopamine not be used for renal protection (Grade 1A).
We recommend that all patients requiring vasopressors have an arterial line placed as soon as practical if resources are available (Grade 1D).
G. Inotropic Therapy
We recommend a dobutamine infusion be administered in the presence of myocardial dysfunction as suggested by elevated cardiac filling pressures and low cardiac output (Grade 1C).
We recommend against the use of a strategy to increase cardiac index to predetermined supranormal levels (Grade 1B).
We suggest intravenous hydrocortisone be given only to adult septic shock patients after blood pressure is identified to be poorly responsive to fluid resuscitation and vasopressor therapy (Grade 2C).
We suggest the ACTH stimulation test not be used to identify the subset of adults with septic shock who should receive hydrocortisone (Grade 2B).
We suggest that patients with septic shock should not receive dexamethasone if hydrocortisone is available (Grade 2B).
We suggest the daily addition of oral fludrocortisone (50 μg) if hydrocortisone is not available and the steroid that is substituted has no significant mineralocorticoid activity. Fludrocortisone is considered optional if hydrocortisone is used (Grade 2C).
We suggest clinicians wean the patient from steroid therapy when vasopressors are no longer required (Grade 2D).
We recommend doses of corticosteroids comparable to > 300 mg hydrocortisone daily not be used in severe sepsis or septic shock for the purpose of treating septic shock (Grade 1A).
We recommend corticosteroids not be administered for the treatment of sepsis in the absence of shock. There is, however, no contraindication to continuing maintenance steroid therapy or to using stress does steroids if the patient's endocrine or corticosteroid administration history warrants (Grade 1D).
I. Recombinant Human Activated Protein C (rhAPC)
We suggest that adult patients with sepsis induced organ dysfunction associated with a clinical assessment of high risk of death, most of whom will have APACHE II ≥ 25 or multiple organ failure, receive rhAPC if there are no contraindications (Grade 2B except for patients within 30 days of surgery where it is Grade 2C). Relative contraindications should also be considered in decision making.
We recommend that adult patients with severe sepsis and low risk of death, most of whom will have APACHE II < 20 or one organ failure, do not receive rhAPC (Grade 1A).
PROWESS involved 1,690 patients and documented 6.1% in absolute total mortality reduction with a relative risk reduction (RRR) of 19.4%, 95% CI 6.6–30.5%, number needed to treat (NNT):16 . Controversy associated with the results focused on a number of subgroup analyses. Subgroup analyses have the potential to mislead due to the absence of an intent to treat, sampling bias, and selection error . The analyses suggested increasing absolute and relative risk reduction with greater risk of death using both higher APACHE II scores and greater number of organ failures . This led to drug approval for patients with high risk of death (such as APACHE II ≥ 25) and more than one organ failure in Europe.
The ADDRESS trial involved 2,613 patients judged to have a low risk of death at the time of enrollment. 28 day mortality from all causes was 17% on placebo vs. 18.5% on APC, relative risk (RR) 1.08, 95% CI 0.92–1.28 . Again, debate focused on subgroup analyses; analyses restricted to small subgroups of patients with APACHE II score over 25, or more than one organ failures which failed to show benefit; however these patient groups also had a lower mortality than in PROWESS.
Relative risk reduction of death was numerically lower in the subgroup of patients with recent surgery (n = 502) in the PROWESS trial (30.7% placebo vs. 27.8% APC)  when compared to the overall study population (30.8% placebo vs. 24.7% APC) . In the ADDRESS trial, patients with recent surgery and single organ dysfunction who received APC had significantly higher 28 day mortality rates (20.7% vs. 14.1%, p = 0.03, n = 635) .
Serious adverse events did not differ in the studies [115, 116, 117] with the exception of serious bleeding, which occurred more often in the patients treated with APC: 2% vs. 3.5% (PROWESS; p = 0.06) ; 2.2% vs. 3.9% (ADDRESS; p < 0.01) ; 6.5% (ENHANCE, open label) . The pediatric trial and implications are discussed in the pediatric consideration section of this manuscript (see Appendix C for absolute contraindications to use of rhAPC and prescribing information for relative contraindications).
Intracranial hemorrhage (ICH) occurred in the PROWESS trial in 0.1% (placebo) and 0.2% (APC) (n. s.) , in the ADDRESS trial 0.4% (placebo) vs. 0.5% (APC) (n. s.) ; in ENHANCE 1.5% . Registry studies of rhAPC report higher bleeding rates than randomized controlled trials, suggesting that the risk of bleeding in actual practice may be greater than reported in PROWESS and ADDRESS [120, 121].
The two RCTs in adult patients were methodologically strong, precise, and provide direct evidence regarding death rates. The conclusions are limited, however, by inconsistency that is not adequately resolved by subgroup analyses (thus the designation of moderate quality evidence). Results, however, consistently fail to show benefit for the subgroup of patients at lower risk of death, and consistently show increases in serious bleeding. The RCT in pediatric severe sepsis failed to show benefit and has no important limitations. Thus, for low risk and pediatric patients, we rate the evidence as high quality.
For adult use there is probable mortality reduction in patients with clinical assessment of high risk of death, most of whom will have APACHE II ≥ 25 or multiple organ failure. There is likely no benefit in patients with low risk of death, most of whom will have APACHE II < 20 or single organ dysfunction. The effects in patients with more than one organ failure but APACHE II < 25 are unclear and in that circumstance one may use clinical assessment of the risk of death and number of organ failures to support decision. There is a certain increased risk of bleeding with administration of rhAPC which may be higher in surgical patients and in the context of invasive procedures. Decision on utilization depends upon assessing likelihood of mortality reduction versus increases in bleeding and cost (see appendix D for nominal committee vote on recommendation for rhAPC). A European Regulatory mandated randomized controlled trial of rhAPC vs. placebo in patients with septic shock is now ongoing .
J. Blood Product Administration
Once tissue hypoperfusion has resolved and in the absence of extenuating circumstances, such as myocardial ischemia, severe hypoxemia, acute hemorrhage, cyanotic heart disease, or lactic acidosis (see recommendations for initial resuscitation), we recommend that red blood cell transfusion occur when hemoglobin decreases to < 7.0 g/dL (< 70 g/L) to target a hemoglobin of 7.0–9.0 g/dL (70–90 g/L) in adults (Grade 1B).
We recommend that erythropoietin not be used as a specific treatment of anemia associated with severe sepsis, but may be used when septic patients have other accepted reasons for administration of erythropoietin such as renal failure-induced compromise of red blood cell production (Grade 1B).
We suggest that fresh frozen plasma not be used to correct laboratory clotting abnormalities in the absence of bleeding or planned invasive procedures (Grade 2D).
We recommend against antithrombin administration for the treatment of severe sepsis and septic shock (Grade 1B).
In patients with severe sepsis, we suggest that platelets should be administered when counts are < 5000/mm3 (5 × 109/L) regardless of apparent bleeding. Platelet transfusion may be considered when counts are 5,000–30,000/mm3 (5–30 × 109/L) and there is a significant risk of bleeding. Higher platelet counts (≥ 50,000/mm3 (50 × 109/L)) are typically required for surgery or invasive procedures (Grade 2D).
II. Supportive Therapy of Severe Sepsis
A. Mechanical Ventilation of Sepsis-Induced Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS).
We recommend that clinicians target a tidal volume of 6 ml/kg (predicted) body weight in patients with ALI/ARDS (Grade 1B).
We recommend that plateau pressures be measured in patients with ALI/ARDS and that the initial upper limit goal for plateau pressures in a passively inflated patient be ≤ 30 cm H2O. Chest wall compliance should be considered in the assessment of plateau pressure (Grade 1C).
High tidal volumes that are coupled with high plateau pressures should be avoided in ALI/ARDS. Clinicians should use as a starting point the objective of reducing tidal volumes over 1–2 hrs from its initial value toward the goal of a “low” tidal volume (≈ 6 mL per kilogram of predicted body weight) achieved in conjunction with an end-inspiratory plateau pressure ≤ 30 cm H2O. If plateau pressure remains > 30 after reduction of tidal volume to 6 ml/kg/PBW, tidal volume should be reduced further to as low as 4 ml/kg/PBW (see Appendix E for ARDSnet ventilator management and formula to calculate predicted body weight).
No single mode of ventilation (pressure control, volume control, airway pressure release ventilation, high frequency ventilation, etc.) has been consistently shown advantageous when compared with any other that respects the same principles of lung protection.
We recommend that hypercapnia (allowing PaCO2 to increase above its pre-morbid baseline, so-called permissive hypercapnia) be allowed in patients with ALI/ARDS if needed to minimize plateau pressures and tidal volumes (Grade 1C).
We recommend that positive end-expiratory pressure (PEEP) be set so as to avoid extensive lung collapse at end-expiration (Grade 1C).
We suggest prone positioning in ARDS patients requiring potentially injurious levels of FIO2 or plateau pressure who are not at high risk for adverse consequences of positional changes in those facilities who have experience with such practices (Grade 2C).
A) Unless contraindicated, we recommend mechanically ventilated patients be maintained with the head of the bed elevated to limit aspiration risk and to prevent the development of ventilator-associated pneumonia (Grade 1B).
B) We suggest that the head of bed is elevated approximately 30–45 degrees (Grade 2C).
We suggest that noninvasive mask ventilation (NIV) only be considered in that minority of ALI/ARDS patients with mild-moderate hypoxemic respiratory failure (responsive to relatively low levels of pressure support and PEEP) with stable hemodynamics who can be made comfortable and easily arousable, who are able to protect the airway, spontaneously clear the airway of secretions, and are anticipated to recover rapidly from the precipitating insult. A low threshold for airway intubation should be maintained (Grade 2B).
We recommend that a weaning protocol be in place, and mechanically ventilated patients with severe sepsis undergo spontaneous breathing trials on a regular basis to evaluate the ability to discontinue mechanical ventilation when they satisfy the following criteria: a) arousable; b) hemodynamically stable (without vasopressor agents); c) no new potentially serious conditions; d) low ventilatory and end-expiratory pressure requirements; and e) FIO2 requirements that could be safely delivered with a face mask or nasal cannula. If the spontaneous breathing trial is successful, consideration should be given for extubation (see Appendix E). Spontaneous breathing trial options include a low level of pressure support, continuous positive airway pressure (≈ 5 cm H2O) or a T-piece (Grade 1A).
We recommend against the routine use of the pulmonary artery catheter for patients with ALI/ARDS (Grade 1A).
To decrease days of mechanical ventilation and ICU length of stay we recommend a conservative fluid strategy for patients with established acute lung injury who do not have evidence of tissue hypoperfusion (Grade 1C).
B. Sedation, Analgesia, and Neuromuscular Blockade in Sepsis
We recommend sedation protocols with a sedation goal when sedation of critically ill mechanically ventilated patients with sepsis is required (Grade 1B).
A report describing the implementation of protocols, including sedation and analgesia, using a short-cycle improvement methodology in the management of critically ill patients demonstrated a decrease in the cost per patient day and a decrease of ICU length of stay . Furthermore, a prospective before-and-after study on the implementation of a sedation protocol demonstrated enhanced quality of sedation with reduced drug costs. Although this protocol also may have contributed to a longer duration of mechanical ventilation, ICU discharge was not delayed . Despite the lack of evidence regarding the use of subjective methods of evaluation of sedation in septic patients, the use of a sedation goal has been shown to decrease the duration of mechanical ventilation in critically ill patients . Several subjective sedation scales have been described in the medical literature. Currently, however, there is not a clearly superior sedation evaluation methodology against which these sedation scales can be evaluated . The benefits of sedation protocols appear to outweigh the risks.
We recommend intermittent bolus sedation or continuous infusion sedation to predetermined end points (e. g., sedation scales) with daily interruption/lightening of continuous infusion sedation with awakening and retitration if necessary for sedation administration to septic mechanically ventilated patients (Grade 1B).
Similarly, a prospective, controlled study in 128 mechanically-ventilated adults receiving continuous intravenous sedation demonstrated that a daily interruption in the “continuous” sedative infusion until the patient was awake decreased the duration of mechanical ventilation and ICU length of stay . Although the patients did receive continuous sedative infusions in this study, the daily interruption and awakening allowed for titration of sedation, in effect, making the dosing intermittent. Systematic (protocolized) titration to a predefined end point has also been shown to alter outcome . Additionally, a randomized prospective blinded observational study demonstrated that although myocardial ischemia is common in critically ill ventilated patients, daily sedative interruption is not associated with an increased occurrence of myocardial ischemia . Thus, the benefits of daily interruption of sedation appear to outweigh the risks. These benefits include potentially shorter duration of mechanical ventilation and ICU stay, better assessment of neurologic function, and reduced costs.
We recommend that NMBAs be avoided if possible in the septic patient due to the risk of prolonged neuromuscular blockade following discontinuation. If NMBAs must be maintained, either intermittent bolus as required or continuous infusion with monitoring the depth of blockade with train-of-four monitoring should be used (Grade 1B).
The most common indication for NMBA use in the ICU is to facilitate mechanical ventilation . When appropriately utilized, NMBAs may improve chest wall compliance, prevent respiratory dyssynchrony, and reduce peak airway pressures . Muscle paralysis may also reduce oxygen consumption by decreasing the work of breathing and respiratory muscle blood flow . However, a randomized, placebo-controlled clinical trial in patients with severe sepsis demonstrated that oxygen delivery, oxygen consumption, and gastric intramucosal pH were not improved during profound neuromuscular blockade .
An association between NMBA use and myopathies and neuropathies has been suggested by case studies and prospective observational studies in the critical care population [195, 198, 199, 200, 201]. The mechanisms by which NMBA's produced or contribute to myopathies and neuropathies in critically ill patients are presently unknown. There appears to be an added association with the concurrent use o NMBA's and steroids. Although no specific studies exist specific to the septic patient population, it seems clinically prudent based on existent knowledge that NMBA's not be administered unless there is a clear indication for neuromuscular blockade that can not be safely achieved with appropriate sedation and analgesia'' .
Only one prospective, randomized clinical trial has evaluated peripheral nerve stimulation vs. standard clinical assessment in ICU patients. Rudis et al.  randomized 77 critically ill patients requiring neuromuscular blockade in the ICU to receive dosing of vecuronium based on train-of-four stimulation or clinical assessment (control). The peripheral nerve stimulation group received less drug and recovered neuromuscular function and spontaneous ventilation faster than the control group. Nonrandomized observational studies have suggested that peripheral nerve monitoring reduces or has no effect on clinical recovery from NMBAs in the ICU setting [203, 204].
Benefits to neuromuscular monitoring, including faster recovery of neuromuscular function and, shorter intubation times, appear to exist. A potential for cost savings (reduced total dose of NMBAs and shorter intubation times) also may exist, although this has not been studied formally.
C. Glucose Control
We recommend that, following initial stabilization, patients with severe sepsis and hyperglycemia who are admitted to the ICU receive IV insulin therapy to reduce blood glucose levels (Grade 1B).
We suggest use of a validated protocol for insulin dose adjustments and targeting glucose levels to the < 150 mg/dl range (Grade 2C).
We recommend that all patients receiving intravenous insulin receive a glucose calorie source and that blood glucose values be monitored every 1–2 hours until glucose values and insulin infusion rates are stable and then every 4 hours thereafter (Grade 1C).
We recommend that low glucose levels obtained with point-of-care testing of capillary blood be interpreted with caution, as such measurements may overestimate arterial blood or plasma glucose values (Grade 1B).
One large before-and-after observational trial showed a 29% relative and 6.1% absolute reduction in mortality and a 10.8% reduction in median ICU LOS . In a subgroup of 53 patients with septic shock there was an absolute mortality reduction of 27% and a relative reduction of 45% (p = 0.02). Two additional observational studies report an association of mean glucose levels with reductions in mortality, polyneuropathy, acute renal failure, nosocomial bacteremia, and number of transfusions, and suggest a glucose threshold for improved mortality lies somewhere between 145 and 180 mg/dl [208, 209]. However, a large observational study (n = 7,049) suggested that both a lower mean glucose and less variation of blood glucose may be important . A meta-analysis of 35 trials on insulin therapy in critically ill patients, including 12 randomized trials, demonstrated a 15% reduction in short term mortality (RR 0.85, 95% confidence interval 0.75–0.97) but did not include any studies of insulin therapy in medical ICUs .
Two additional multicenter RCTs of intensive insulin therapy, one focusing on patients with severe sepsis (VISEP) and the second on medical and surgical ICU patients, failed to demonstrate improvement in mortality, but are not yet published [212, 213]. Both stopped earlier than planned because of high rates of hypoglycemia and adverse events in the intensive insulin groups. A large RCT that is planned to compare targeting 80–110 mg/dl (4.5–6.0 mmol/L) versus 140–180 mg/dl (8–10 mmol/L) and recruit more than 6,000 patients (Normoglycemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation, or NICE-SUGAR) is ongoing .
Several factors may affect the accuracy and reproducibility of point-of-care testing of blood capillary blood glucose, including the type and model of the device used, user expertise, and patient factors including hematocrit (false elevation with anemia), PaO2, and drugs . One report showed overestimation of arterial plasma glucose values by capillary point-of-care testing sufficient to result in different protocol-specified insulin dose titration. The disagreement between protocol-recommended insulin doses was largest when glucose values were low . A recent review of 12 published insulin infusion protocols for critically ill patients showed wide variability in insulin dose recommendations and variable glucose control during simulation . This lack of consensus about optimal dosing of IV insulin may reflect variability in patient factors (severity of illness, surgical vs. medical settings, etc) or practice patterns (e. g., approaches to feeding, IV dextrose) in the environments in which these protocols were developed and tested. Alternatively, some protocols may be more effective than other protocols. This conclusion is supported by the wide variability in hypoglycemia rates reported with protocols [205, 206, 207, 212, 213]. Thus, the use of a validated and safe intensive insulin protocol is important not only for clinical care but also for the conduct of clinical trials to avoid hypoglycemia, adverse events, and premature termination of these trials before the efficacy signal, if any, can be determined.
The finding of reduced morbidity and mortality within the longer ICU length of stay subsets along with acceptable cost weighed heavily on our recommendation to attempt glucose control after initial stabilization of the patient with hyperglycemia and severe sepsis. However, the mortality benefit and safety of intensive insulin therapy (goal to normalize blood glucose) has been questioned by 2 recent trials and we recommend maintaining glucose levels < 150 mg/dl until recent and ongoing trials are published or completed. Further study of protocols that have been validated to be safe and effective for controlling blood glucose concentrations and blood glucose variation in the severe sepsis population are needed.
D. Renal Replacement
We suggest that continuous renal replacement therapies and intermittent hemodialysis are equivalent in patients with severe sepsis and acute renal failure (Grade 2B).
We suggest the use of continuous therapies to facilitate management of fluid balance in hemodynamically unstable septic patients (Grade 2D).
Concerning the hemodynamic tolerance of each method, no current evidence exists to support a better tolerance with continuous treatments. Only 2 prospective studies [230, 233] have reported a better hemodynamic tolerance with continuous treatment, with no improvement in regional perfusion  and no survival benefit . Four other prospective studies did not find any significant difference in mean arterial pressure or drop in systolic pressure between the 2 methods [229, 231, 232, 234]. Concerning fluid balance management, 2 studies report a significant improvement in goal achievement with continuous methods [228, 230]. In summary, current evidence is insufficient to draw strong conclusions regarding the mode of replacement therapy for acute renal failure in septic patients.
Four randomized, controlled trials have addressed whether the dose of continuous renal replacement affects outcomes in patients with acute renal failure [235, 236, 237, 238]. Three found improved mortality in patients receiving higher doses of renal replacement [235, 237, 238], while one  did not. None of these trials was conducted specifically in patients with sepsis. Although the weight of current evidence suggests that higher doses of renal replacement may be associated with improved outcomes, these results may not be easily generalizable. The results of 2 very large multicenter randomized trials comparing the dose of renal replacement (ATN in the United States and RENAL in Australia and New Zealand) will be available in 2008 and will greatly inform practice.
E. Bicarbonate Therapy
We recommend against the use of sodium bicarbonate therapy for the purpose of improving hemodynamics or reducing vasopressor requirements in patients with hypoperfusion-induced lactic acidemia with pH ≥ 7.15 (Grade 1B).
F. Deep Vein Thrombosis Prophylaxis
We recommend that severe sepsis patients receive deep vein thrombosis (DVT) prophylaxis with either (a) low-dose unfractionated heparin (UFH) administered b.i.d. or t.i.d. or (b) daily low-molecular weight heparin (LMWH) unless there are contraindications (i. e., thrombocytopenia, severe coagulopathy, active bleeding, recent intracerebral hemorrhage) (Grade 1A).
We recommend that septic patients who have a contraindication for heparin use receive mechanical prophylactic device such as graduated compression stockings (GCS) or intermittent compression devices (ICD) unless contraindicated (Grade 1A).
We suggest that in very high-risk patients such as those who have severe sepsis and history of DVT, trauma, or orthopedic surgery, a combination of pharmacologic and mechanical therapy be used unless contraindicated or not practical (Grade 2C).
We suggest that in patients at very high risk, LMWH be used rather than UFH as LMWH is proven superior in other high-risk patients (Grade 2C).
Nine randomized placebo controlled clinical trials of DVT prophylaxis in general populations of acutely ill patients exist [242, 243, 244, 245, 246, 247, 248, 249, 250]. All 9 trials showed reduction in DVT or PE. The prevalence of infection/sepsis was 17% in all studies in which this was ascertainable, with a 52% prevalence of infection/sepsis patients in the study that included ICU patients only. Benefit of DVT prophylaxis is also supported by meta-analyses [251, 252]. With that in mind, DVT prophylaxis would appear to have a high grade for quality of evidence (A). As the risk of administration to the patient is small, the gravity of the potential result of not administering is great, and the cost is low, the grading of the strength of the recommendation is strong. The evidence supports equivalency of LMWH and UFH in general medical populations. A recent meta-analysis comparing b.i.d. and t.i.d. UFH demonstrated that t.i.d. UFH produced better efficacy and b.i.d. less bleeding . Practitioners should use underlying risk for VTE and bleeding to individualize choice of b.i.d. versus t.i.d.
The cost of LMWH is greater and the frequency of injection is less. UFH is preferred over LMWH in patients with moderate to severe renal dysfunction.
Mechanical methods (ICD and GCS) are recommended when anticoagulation is contraindicated or as an adjunct to anticoagulation in the very high-risk patients [254, 255, 256]. In very high-risk patients, LMWH is preferred over UFH [257, 258, 259]. Patients receiving heparin should be monitored for development of heparin-induced thrombocytopenia (HIT).
G. Stress Ulcer Prophylaxis (SUP)
We recommend that stress ulcer prophylaxis using H2 blocker (Grade 1A) or proton pump inhibitor PPI (Grade 1B) be given to patients with severe sepsis to prevent upper GI bleed. Benefit of prevention of upper GI bleed must be weighed against potential effect of an increased stomach pH on development of ventilator-associated pneumonia.
Rationale. Although no study has been performed specifically in patients with severe sepsis, trials confirming the benefit of stress ulcer prophylaxis reducing upper GI bleeds in general ICU populations would suggest that 20–25% of patients enrolled in these types of trials have sepsis [260, 261, 262, 263]. This benefit should be applicable to patients with severe sepsis and septic shock. In addition, the conditions shown to benefit from stress ulcer prophylaxis (coagulopathy, mechanical ventilation, hypotension) are frequently present in patients with severe sepsis and septic shock [264, 265].
Although there are individual trials that have not shown benefit from SUP, numerous trials and a meta-analysis show reduction in clinically significant upper GI bleeding, which we consider significant even in the absence of proven mortality benefit [266, 267, 268, 269]. The benefit of prevention of upper GI bleed must be weighed against the potential effect of increased stomach pH on greater incidence of ventilator-associated pneumonia . Those severe sepsis patients with the greatest risk of upper GI bleeding are likely to benefit most from stress ulcer prophylaxis. The rationale for the preference for suppression of acid production over sulcrafate was based on the study of 1200 patients by Cook et al comparing H2 blockers and sucralfate and a meta-analysis [271, 272]. 2 studies support equivalency between H2 blockers and PPIs. One was in very ill ICU patients. The second study is larger and demonstrates non-inferiority of omeprazole suspension for clinically significant stress ulcer bleeding [273, 274]. No data relating to utility of enteral feeding in stress ulcer prophylaxis exist. Patients should be periodically evaluated for continued need for prophylaxis.
H. Selective Digestive Tract Decontamination (SDD)
The guidelines group was evenly split on the issue of SDD, with equal numbers weakly in favor and against recommending the use of SDD (see appendix H). The committee therefore chose not to make a recommendation for the use of SDD specifically in severe sepsis at this time. The final consensus on use of SDD in severe sepsis was achieved at the last nominal committee meeting and subsequently approved by the entire committee (see Appendix H for committee vote).
Rationale. The cumulative conclusion from the literature demonstrates that prophylactic use of SDD (enteral non-absorbable antimicrobials and short-course intravenous antibiotics) reduces infections, mainly pneumonia, and mortality in the general population of critically ill and trauma patients [275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286] without promoting emergence of resistant Gram negative bacteria. Post hoc subgroup analyses [287, 288] of two prospective blinded studies [289, 290] suggest that SDD reduces nosocomial (secondary) infections in ICU patients admitted with primary infections  and may reduce mortality . No studies of SDD specifically focused on patients with severe sepsis or septic shock. The use of SDD in severe sepsis patients would be targeted toward preventing secondary infection. As the main effect of SDD is in preventing ventilator-associated pneumonia (VAP), studies comparing SDD with non-antimicrobial interventions such as ventilator bundles for reducing VAP are needed. Further investigation is required to determine the comparative efficacy of these two interventions, separately or in combination. Although studies incorporating enteral vancomycin in the regimen appear to be safe [291, 292, 293] concerns persist about the potential for emergence of resistant Gram positive infections.
I. Consideration for Limitation of Support
We recommend that advance care planning, including the communication of likely outcomes and realistic goals of treatment, be discussed with patients and families (Grade 1D).
Rationale. Decisions for less aggressive support or withdrawal of support may be in the patient's best interest. [294, 295, 296] Too frequently, inadequate physician/family communication characterizes end-of-life care in the ICU. The level of life support given to ICU patients may not be consistent with their wishes. Early and frequent caregiver discussions with patients who face death in the ICU and with their loved ones may facilitate appropriate application and withdrawal of life-sustaining therapies. A recent RCT demonstrated reduction of anxiety and depression in family members when end-of-life meetings were carefully planned, conducted, included advance care planning, and provided relevant information about diagnosis, prognosis, and treatment .
III. Pediatric Considerations in Severe Sepsis
While sepsis in children is a major cause of mortality, the overall mortality from severe sepsis in children is much lower that that in adults, estimated at about 10% . The definitions for severe sepsis and septic shock in children are similar but not identical to the definitions in adults . In addition to age-appropriate differences in vital signs, the definition of systemic inflammatory response syndrome requires the presence of either temperature or leukocyte abnormalities. The presence of severe sepsis requires sepsis plus cardiovascular dysfunction or ARDS or 2 or more other organ dysfunctions .
We recommend antibiotics be administered within one hour of the identification of severe sepsis, after appropriate cultures have been obtained (Grade 1D).
B. Mechanical Ventilation
No graded recommendations.
Due to low functional residual capacity, young infants and neonates with severe sepsis may require early intubation . Drugs used for intubation have important side effects in these patients, for example, concerns have been raised about the safety of using etomidate in children with meningococcal sepsis because of adrenal suppression effect . The principles of lung-protective strategies are applied to children as they are to adults.
C. Fluid Resuscitation
We suggest initial resuscitation begin with infusion of crystalloids with boluses of 20 mL/kg over 5–10 minutes, titrated to clinical monitors of cardiac output, including heart rate, urine output, capillary refill, and level of consciousness (Grade 2C).
Children normally have a lower blood pressure than adults, and fall in blood pressure can be prevented by vasoconstriction and increasing heart rate. Therefore, blood pressure by itself is not a reliable end point for assessing the adequacy of resuscitation. However, once hypotension occurs, cardiovascular collapse may soon follow. Hepatomegaly occurs in children who are fluid overloaded and can be a helpful sign of adequacy of fluid resuscitation. Large fluid deficits typically exist and initial volume resuscitation usually requires 40–60 mL/kg but can be much higher [304, 305, 306, 307, 308]. However, the rate of fluid administration should be reduced substantially when there are (clinical) signs of adequate cardiac filling without hemodynamic improvement.
D. Vasopressors/Inotropes (should be used in volume loaded patients with fluid refractory shock)
We suggest dopamine as the first choice of support for the pediatric patient with hypotension refractory to fluid resuscitation (Grade 2C).
Dopamine-refractory shock may reverse with epinephrine or norepinephrine infusion .
We suggest that patients with low cardiac output and elevated systemic vascular resistance states (cool extremities, prolonged capillary refill, decreased urine output but normal blood pressure following fluid resuscitation) be given dobutamine (Grade 2C).
E. Therapeutic End Points
We suggest that the therapeutic end points of resuscitation of septic shock be normalization of the heart rate, capillary refill of < 2 secs, normal pulses with no differential between peripheral and central pulses, warm extremities, urine output > 1mL.kg −1.hr−1, and normal mental status  (Grade 2C).
F. Approach to Pediatric Septic Shock
We suggest that hydrocortisone therapy be reserved for use in children with catecholamine resistance and suspected or proven adrenal insufficiency (Grade 2C).
Adrenal insufficiency in pediatric severe sepsis is associated with a poor prognosis . No strict definitions exist, but absolute adrenal insufficiency in the case of catecholamine-resistant septic shock is assumed at a random total cortisol concentration < 18 μg/dL (496 nmol/L). A post 30- or 60-min ACTH stimulation test increase in cortisol of ≤ 9 μg/dL (248 mmol/L) has been used to define relative adrenal insufficiency. The treatment of relative adrenal insufficiency in children with septic shock is controversial. A retrospective study from a large administrative database recently reported that the use of any corticosteroids in children with severe sepsis was associated with increased mortality (OR 1.9 95% CI 1.7–2.2) . While steroids may have been given preferentially to more severely ill children, the use of steroids was an independent predictor of mortality in multivariable analysis . Given the lack of data in children and potential risk, steroids should not be used in those children who do not meet minimal criteria for adrenal insufficiency. A randomized, controlled trial in children with septic shock is very much needed.
H. Protein C and Activated Protein C
We recommend against the use rhAPC in children (Grade 1B).
I. DVT Prophylaxis
We suggest the use of DVT prophylaxis in post-pubertal children with severe sepsis (Grade 2C).
Most DVTs in young children are associated with central venous catheters. Femoral venous catheters are commonly used in children, and central venous catheter-associated DVTs occur in approximately 25% of children with a femoral central venous catheter. Heparin-bonded catheters may decrease the risk of catheter-associated DVT and should be considered for use in children with severe sepsis. [325, 326] No data on the efficacy of unfractionated or low-molecular weight heparin prophylaxis to prevent catheter-related DVT in children in the ICU exist.
J. Stress Ulcer Prophylaxis
No graded recommendations.
Studies have shown that the rate of clinically important gastrointestinal bleeding in children occurs at rates similar to adults [327, 328]. As in adults, coagulopathy and mechanical ventilation are risk factors for clinically important gastrointestinal bleeding. Stress ulcer prophylaxis strategy is commonly used in mechanically-ventilated children, usually with H2 blockers. Its effect is not known.
K. Renal Replacement Therapy
No graded recommendations.
Continuous veno-venous hemofiltration (CVVH) may be clinically useful in children with anuria/severe oliguria and fluid overload, but no large RCTs have been performed comparing CVVH with intermittent dialysis. A retrospective study of 113 critically ill children reported that children with less fluid overload before CVVH had better survival, especially in those children with dysfunction of 3 or more organs . CVVH or other renal replacement therapy should be instituted in children with anuria/severe oliguria before significant fluid overload occurs.
L. Glycemic Control
No graded recommendations.
In general, infants are at risk for developing hypoglycemia when they depend on intravenous fluids. This means that a glucose intake of 4–6 mg.kg−1.min−1 or maintenance fluid intake with glucose 10%/NaCl containing solution is advised. Associations have been reported between hyperglycemia and an increased risk of death and longer length of stay . A recent retrospective PICU study reported associations of hyperglycemia, hypoglycemia, and glucose variability with length of stay and mortality rates.  No studies in pediatric patients (without diabetes mellitus) analyzing the effect of strict glycemic control using insulin exist. In adults, the recommendation is to maintain a serum glucose below 150 mg/dL. Insulin therapy to avoid long periods of hyperglycemia seems sensible in children as well, but the optimal goal glucose is not known. However, continuous insulin therapy should only be done with frequent glucose monitoring in view of the risks for hypoglycemia.
We recommend sedation protocols with a sedation goal when sedation of critically ill mechanically ventilated patients with sepsis is required (Grade 1D).
N. Blood Products
No graded recommendations.
The optimal hemoglobin for a critically ill child with severe sepsis is not known. A recent multicenter trial reported similar outcomes in stable critically ill children managed with a transfusion threshold of 7 gm/dl compared to those managed with a transfusion threshold of 9.5 g/dL . Whether a lower transfusion trigger is safe or appropriate in the initial resuscitation of septic shock has not been determined.
O. Intravenous Immunoglobulin
We suggest that immunoglobulin may be considered in children with severe sepsis (Grade 2C).
P. Extracorporeal membrane oxygenation (ECMO)
We suggest that use of ECMO be limited to refractory pediatric septic shock and/or respiratory failure that cannot be supported by conventional therapies (Grade 2C).
Although the pediatric considerations section of this manuscript offers important information to the practicing pediatric clinician for the management of critically ill children with sepsis, the reader is referred to the references at the end of the document for more in-depth descriptions of appropriate management of pediatric septic patients.
Summary and Future Directions
The reader is reminded that although this document is static, the optimum treatment of severe sepsis and septic shock is a dynamic and evolving process. New interventions will be proven and established interventions, as stated in the current recommendations, may need modification. This publication represents an ongoing process. The Surviving Sepsis Campaign and the consensus committee members are committed to updating the guidelines on a regular basis as new interventions are tested and published in the literature.
Although evidence-based recommendations have been frequently published in the medical literature, documentation of impact on patient outcome is limited . There is, however, growing evidence that protocol implementation associated with education and performance feedback does change clinician behavior and may improve outcomes in and reduce costs in severe sepsis [20, 24, 25]. Phase III of the Surviving Sepsis Campaign targets the implementation of a core set of the previous recommendations in hospital environments where change in behavior and clinical impact are being measured. The sepsis bundles were developed in collaboration with the Institute of Healthcare Improvement . Concurrent or retrospective chart review will identify and track changes in practice and clinical outcome. Software and software support is available at no cost in 7 languages, allowing bedside data entry and allows creation of regular reports for performance feedback. The Campaign also offers significant program support and educational materials at no cost to the user (www.survivingsepsis.org ).
Engendering evidence-based change in clinical practice through multi-faceted strategies while auditing practice and providing feedback to healthcare practitioners is the key to improving outcomes in severe sepsis. Nowhere is this more evident than in the worldwide enthusiasm for Phase III of the Campaign, a performance improvement program using SSC guideline-based sepsis bundles. Using the guidelines as the basis, the bundles have established a global best practice for the management of critically ill patients with severe sepsis. As of November 2007, over 12,000 patients have been entered into the SSC central database, representing the efforts of 239 hospitals in 17 countries. Change in practice and potential effect on survival are being measured.
Acknowledgment of Support As mentioned above in the methods section, the Surviving Sepsis Campaign (SSC) is partially funded by unrestricted educational industry grants, including those from Edwards LifeSciences, Eli Lilly and Company, and Philips Medical Systems. SSC also received funding from the Coalition for Critical Care Excellence of the Society of Critical Care Medicine. The great majority of industry funding has come from Eli Lilly and Company.
Current industry funding for the Surviving Sepsis Campaign is directed to the performance improvement initiative. No industry funding was used for committee meetings. No honoraria were provided to committee members. The revision process was funded primarily by the Society of Critical Care Medicine, with the sponsoring professional organizations providing travel expenses for their designated delegate to the guidelines revision meeting where needed.
Other Acknowledgements Toni Piper and Rae McMorrow for their assistance in bringing the manuscript together. Gordon Guyatt and Henry Masur, M.D. for their guidance on grading of evidence and antibiotic recommendations respectively.
Nine of the 11 organizations that sponsored the first guidelines are sponsors of the revision. Four additional national organizations (Canadian Critical Care Society, Japanese Association for Acute Medicine, Japanese Society of Intensive Care Medicine, and Society of Hospital Medicine), the World Federation of Societies of Intensive and Critical Care Medicine and two sepsis organizations (German Sepsis Society and the Latin American Sepsis Institute) have also come on board as sponsors. Two organizations that sponsored the first guidelines (American Thoracic Society and Australian and New Zealand Intensive Care Society) elected not to sponsor the revision.
Introduction and Methods
- 5.Dombrovskiy VY, Martin AA, Sunderram J, Paz HL (2007) Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 35:1414–1415Google Scholar
- 6.Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM, Surviving Sepsis Campaign Management Guidelines Committee (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873PubMedGoogle Scholar
- 7.Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM, Surviving Sepsis Campaign Management Guidelines Committee (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30:536–555PubMedGoogle Scholar
- 9.GRADE working group (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490–1498Google Scholar
- 11.Schünemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A, Fahy BF, Gould MK, Horan KL, Krishnan JA, Manthous CA, Maurer JR, McNicholas WT, Oxman AD, Rubenfeld G, Turino GM, Guyatt G, ATS Documents Development and Implementation Committee (2006) An Official ATS Statement: Grading the Quality of Evidence and Strength of Recommendations in ATS Guidelines and Recommendations. Am J Respir Crit Care Med 174:605–614PubMedGoogle Scholar
- 13.Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ, Members of the ACCP/SCCM Consensus Conference (1992) Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis. Chest 101:1644–1655 and Crit Care Med 20:864–874Google Scholar
- 14.Sprung CL, Bernard GR, Dellinger RP (2001) Guidelines for the Management of Severe Sepsis and Septic Shock. Intensive Care Med 27(Suppl 1):S1–S134Google Scholar
- 31.Trzeciak S, Dellinger RP, Parrillo JE, Guglielmi M, Bajaj J, Abate NL, Arnold RC, Colilla S, Zanotti S, Hollenberg SM, Microcirculatory Alterations in Resuscitation and Shock Investigators (2007) Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: Relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med 49:88–98PubMedGoogle Scholar
- 39.American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416Google Scholar
- 42.Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006) Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596PubMedGoogle Scholar
- 45.McCabe WR, Jackson GG (1962) Gram negative bacteremia. Arch Intern Med 110:92–100Google Scholar
- 50.Ali MZ, Goetz MB (1997) A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infec Dis 24:796–809Google Scholar
- 51.Amsden GW, Ballow CH, Bertino JS (2000) Pharmacokinetics and Pharmacodynamics of Anti-infective Agents. In: Mandell GL, Bennett JE, Dolin R (Eds) Principles and Practice of Infectious Diseases. Fifth Edition. Philadelphia, Churchill Livingstone, pp 253–261Google Scholar
- 53.Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. www.idsociety.org. Accessed July 10, 2007.
- 56.Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L (2006) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev Jan 25:CD003344Google Scholar
- 57.Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J (2007) Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 25:1888–1895Google Scholar
- 61.O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A, Weinstein RA (2002) Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR 51(RR-10):1–29PubMedGoogle Scholar
- 62.O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A, Weinstein RA, Healthcare Infection Control Practices Advisory Committee (2002) Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 35:1281–1307Google Scholar
- 80.Levy B, Bollaert PE, Charpentier C, Nace L, Audibert G, Bauer P, Nabet P, Larcan A (1997) Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 23:282–287PubMedGoogle Scholar
- 85.Djillali A, Vigno P, Renault A, Blooaert PE, Chrpentier C, Martin C, Troché G, Ricard JD, Nitenberg G, Papazian L, Azouly E, Bellissant E, for the CATS STUDY Group (2007) Norepinephrine plus donutamine versus epinephrine alone for management of septic shock: A randomized trial. Lancet 370:676–684Google Scholar
- 101.Annane D, Sebille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871PubMedGoogle Scholar
- 102.Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27:723–732PubMedGoogle Scholar
- 104.Sprung CL, Annane D, Briegel J, Keh D, Moreno R, Singer M, Weiss Y, Sorenson F (2007) Corticosteroid therapy of septic shock (CORTICUS) (abstract). Am Rev Resp Crit Care Med 175:A507Google Scholar
- 105.Briegel J, Vogeser M, Annane D, Keh D, Moreno R, Singer M, Weiss Y, Sprung CL (2007) Measurement of cortisol in septic shock: Interlaboratory harmonization. Am Rev Resp Crit Care Med 175:A436Google Scholar
- 106.Allolio B, Dorr H, Stuttmann R, Knorr D, Engelhardt D, Winkelmann W (1985) Effect of a single bolus of etomidate upon eight major corticosteroid hormone and plasma ACTH. Clin Ednocrinol (oxf) 22:281–286Google Scholar
- 110.Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, Volk HD, Doecke WD, Falke KJ, Gerlach H (2003) Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167:512–520PubMedGoogle Scholar
Recombinant Human Activated Protein C
- 115.Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group (2001) Efficacy and safety of recombinant human activated protein c for severe sepsis. N Engl J Med 344:699–709PubMedGoogle Scholar
- 116.Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL, Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332–1341PubMedGoogle Scholar
- 117.Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266–2277PubMedGoogle Scholar
- 122.European Medicines Agency. Evaluation of Medicines for Human Use. www.emea.europa.eu/pdfs/human/press/pr/8509607en.pdf. Accessed October 22, 2007.
Blood Product Administration
- 128.Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T, EPO Critical Care Trials Group (2002) Efficacy of recombinant human erythropoietin in critically ill patients. JAMA 28:2827–2835Google Scholar
- 129.College of American Pathologists (1994) Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. JAMA 271:777–781Google Scholar
- 130.Canadian Medical Association Expert Working Group (1997) Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J 156:S1-S24Google Scholar
- 131.American Society of Anaesthesiologists Task Force on Blood Component Therapy (1996) Practice guidelines for blood component therapy. Anesthesiology 84:732–47Google Scholar
- 133.Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, KyberSept Trial Study Group (2001) High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 286:1869–1878PubMedGoogle Scholar
- 134.Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM, KyberSept Investigators (2006) High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety. Crit Care Med 34:285–292PubMedGoogle Scholar
- 135.The Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342:1301–1308Google Scholar
- 136.Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, Takagaki TY, Carvalho CR (1998) Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 338:347–354PubMedGoogle Scholar
- 137.Brochard L, Roudot-Thoraval F, Roupie E, Delclaux C, Chastre J, Fernandez-Mondejar E, Clementi E, Mancebo J, Factor P, Matamis D, Ranieri M, Blanch L, Rodi G, Mentec H, Dreyfuss D, Ferrer M, Brun-Buisson C, Tobin M, Lemaire F (1998) Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. Am J Respir Crit Care Med 158:1831–1838PubMedGoogle Scholar
- 138.Brower RG, Shanholtz CB, Fessler HE, Shade DM, White P Jr, Wiener CM, Teeter JG, Dodd-o JM, Almog Y, Piantadosi S (1999) Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. Crit Care Med 27:1492–1498PubMedGoogle Scholar
- 139.Stewart TE, Meade MO, Cook DJ, Granton JT, Hodder RV, Lapinsky SE, Mazer CD, McLean RF, Rogovein TS, Schouten BD, Todd TR, Slutsky AS (1998) Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. N Engl J Med 338:355–361PubMedGoogle Scholar
- 144.Ferguson ND, Frutos-Vivar F, Esteban A, Anzueto A, Alia I, Brower RG, Stewart TE, Apezteguia C, Gonzalez M, Soto L, Abroug F, Brochard L, Mechanical Ventilation International Study Group (2005) Airway pressures, tidal volumes, and mortality in patients with acute respiratory distress syndrome Crit Care Med 33:21–30Google Scholar
- 148.Weber T, Tschernich H, Sitzwohl C, Ullrich R, Germann P, Zimpfer M, Sladen RN, Huemer G (2000) Tromethamine buffer modifies the depressant effect of permissive hypercapnia on myocardial contractility in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 162:1361–1365PubMedGoogle Scholar
- 152.The National Heart, Lung, and Blood Institute ARDS Clinical Trials Network (2004) Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 351:327–336Google Scholar
- 154.Amato MB, Barbas CS, Medeiros DM, Schettino Gde P, Lorenzi Filho G, Kairalla RA, Deheinzelin D, Morais C, Fernandes Ede O, Takagaki TY, et al. (1995) Beneficial effects of the “open lung approach” with low distending pressures in acute respiratory distress syndrome. A prospective randomized study on mechanical ventilation. Am J Respir Crit Care Med 152:1835–1846PubMedGoogle Scholar
- 159.Gattinoni L, Tognoni G, Pesenti A, Taccone P, Mascheroni D, Labarta V, Malacrida R, Di Giulio P, Fumagalli R, Pelosi P, Brazzi L, Latini R, Prone-Supine Study Group (2001) Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 345:568–573PubMedGoogle Scholar
- 160.Guerin C, Gaillard S, Lemasson S, Ayzac L, Girard R, Beuret P, Palmier B, Le QV, Sirodot M, Rosselli S, Cadiergue V, Sainty JM, Barbe P, Combourieu E, Debatty D, Rouffineau J, Ezingeard E, Millet O, Guelon D, Rodriguez L, Martin O, Renault A, Sibille JP, Kaidomar M (2004) Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. JAMA 292:2379–2387PubMedGoogle Scholar
- 161.Mancebo J, Fernández R, Blanch L, Rialp G, Gordo F, Ferrer M, Rodríguez F, Garro P, Ricart P, Vallverdú I, Gich I, Castaño J, Saura P, Domínguez G, Bonet A, Albert RK (2006) A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. Am J Respir Crit Care Med 173:1233–1239PubMedGoogle Scholar
- 167.Esteban A, Alía I, Tobin MJ, Gil A, Gordo F, Vallverdú I, Blanch L, Bonet A, Vázquez A, de Pablo R, Torres A, de La Cal MA, Macías S (1999) Effect of spontaneous breathing trial duration on outcome of attempts to discontinue mechanical ventilation. Am J Respir Crit Care Med 159:512–518PubMedGoogle Scholar
- 168.Esteban A, Alia I, Gordo F, Fernandez R, Solsona JF, Vallverdu I, Macias S, Allegue JM, Blanco J, Carriedo D, Leon M, de la Cal MA, Taboada F, Gonzalez de Velasco J, Palazon E, Carrizosa F, Tomas R, Suarez J, Goldwasser RS (1997) Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. Am J Respir Crit Care Med 156:459–465PubMedGoogle Scholar
- 175.Richard C, Warszawski J, Anguel N, Deye N, Combes A, Barnoud D, Boulain T, Lefort Y, Fartoukh M, Baud F, Boyer A, Brochard L, Teboul JL, French Pulmonary Artery Catheter Study Group (2003) Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: A randomized controlled trial. JAMA 290:2713–2720PubMedGoogle Scholar
- 176.National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, Wiedemann HP, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL (2006) Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 354:2213–2224PubMedGoogle Scholar
- 177.Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, Laporta DP, Viner S, Passerini L, Devitt H, Kirby A, Jacka M, Canadian Critical Care Clinical Trials Group (2003) A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 348:5–14PubMedGoogle Scholar
- 179.Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, Brampton W, Williams D, Young D, Rowan K, PAC-Man study collaboration (2005) Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-man): A randomised controlled trial. Lancet 366:472–477PubMedGoogle Scholar
- 185.National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, de Boisblanc B, Connors AF Jr, Hite RD, Harabin AL (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564–2575PubMedGoogle Scholar
Sedation, Analgesia and Neuromuscular Blockade
- 189.De Jonghe B, Cook D, Appere-De-Vecchi C, Guyatt G, Meade M, Outin H (2000) Using and understanding sedation scoring systems: a systematic review. Intensive Care Med 20:662–672Google Scholar
- 190.Devlin JW, Boleski G, Mlynarek M, Nerenz DR, Peterson E, Jankowski M, Horst HM, Zarowitz BJ (1999) Motor activity assessment scale: A valid and reliable sedation scale for use with mechanically ventilated patients in an adult surgical intensive care unit. Crit Care Med 27:1271–1275PubMedGoogle Scholar
- 195.Murray MJ, Cowen J, DeBlock H, Erstad B, Gray AW Jr, Tescher AN, McGee WT, Prielipp RC, Susla G, Jacobi J, Nasraway SA Jr, Lumb PD, Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians (2002) Clinical practice guidelines for sustained neuromuscular blockade in the critically ill adult. Crit Care Med 30:142–156PubMedGoogle Scholar
- 197.Freebairn RC, Derrick J, Gomersall CD, Young RJ, Joynt GM (1997) Oxygen delivery, oxygen consumption, and gastric intramucosal pH are not improved by a computer-controlled, closed-loop, vecuronium infusion in severe sepsis and septic shock. Crit Care Medicine 25:72–77Google Scholar
- 202.Rudis MI, Sikora CA, Angus E, Peterson E, Popovich J Jr, Hyzy R, Zarowitz BJ (1997) A prospective randomized controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 25:575–583PubMedGoogle Scholar
- 206.Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R (2006) Intensive Insulin Therapy in the Medical ICU. N Engl J Med 354:449–461Google Scholar
- 210.Egi M, Bellomo R, Stachowski E, French C (2006) Variability in blood glucose concentrations and short-term mortality in critically ill patients. Anesthesiology 105:233–234Google Scholar
- 211.Pittas AG, Siegel RD, Lau J (2004) Insulin therapy for critically ill hospitalized patients. Arch Int Med 164:2005–2011Google Scholar
- 212.Brunkhorst FM, Kuhnt E, Engel C, Meier-Hellmann A, Ragaller M, Quintel M, Weiler N, Grundling M, Oppert M, Deufel T, et al. (2005) Intensive insulin therapy in patient with severe sepsis and septic shock is associated with an increased rate of hypoglycemia – results from a randomized multicenter study (VISEP) [abstract]. Infection 33:19–20Google Scholar
- 213.Preiser JC (2007) Intensive glycemic control in med-surg patients (European Glucontrol trial). Program and abstracts of the Society of Critical Care Medicine 36th Critical Care Congress; February 17–21, 2007; Orlando, FloridaGoogle Scholar
- 214.Current Controlled Trials. A multi-centre, open label, randomised controlled trial of two target ranges for glycaemic control in intensive care unit (ICU) patients. Available from http://controlled-trials.com/isrctn/trial/ISRCTN04968275/0/04968275.html [accessed June 10, 2007].
- 215.Nichols JH (2002) Bedside testing, glucose monitoring, and diabetes management. In: Kost GJ, Principles of Point of Care testing. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
- 218.Mauritz W, Sporn P, Schindler I, Zadrobilek E, Roth E, Appel W (1986) Acute renal failure in abdominal infection. Comparison of hemodialysis and continuous arteriovenous and continuous hemofiltration. Anasth Intensivther Nortfallmed 21:212–217Google Scholar
- 221.Bellomo R, Mansfield D, Rumble S, Shapiro J, Parkin G, Boyce N (1992) Acute renal failure in critical illness: conventional dialysis versus continuous hemodiafiltration. Am Soc Artif Intern Organs J 38:M654–M657Google Scholar
- 223.Kruczinski K, Irvine-Bird K, Toffelmire EB, Morton AR (1993) A comparison of continuous arteriovenous hemofiltration and intermittent hemodialysis in acute renal failure patients in intensive care unit. Am Soc Artif Intern Organs J 38:M778–M781Google Scholar
- 232.Vinsonneau C, Camus C, Combes A, Costa de Beauregard MA, Klouche K, Boulain T, Pallot JL, Chiche JD, Taupin P, Landais P, Dhainaut JF, Hemodiafe Study Group (2006) Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet 368:379–385PubMedGoogle Scholar
- 233.John S, Griesbach D, Baumgärtel M, Weihprecht H, Schmieder RE, Geiger H (2001) Effects of continuous haemofiltration vs intermittent heamodialysis on systemic heamodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial. Nephrol Dial Transplant 16:320–327PubMedGoogle Scholar
- 236.Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J (2002) Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: A prospective, randomized trial. Crit Care Med 30:2205–2211PubMedGoogle Scholar
- 249.Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L (2000) Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD: The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 161:1109–1114PubMedGoogle Scholar
- 250.Kupfer Y, Anwar J, Seneviratne C, et al. (1999) Prophylaxis with subcutaneous heparin significantly reduces the incidence of deep venous thrombophlebitis in the critically ill. Abstr. Am J Crit Care Med (Suppl) 159:A519Google Scholar
- 254.Turpie AG, Hirsh J, Gent M, Julian D, Johnson J (1989) Prevention of deep vein thrombosis in potential neurosurgical patients: a randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med 149:679–681PubMedGoogle Scholar
- 257.German Hip Arthroplasty Trial Group (GHAT) (1992) Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg 111:110–120Google Scholar
- 258.Colwell CW Jr, Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD, Comerota AJ, Skoutakis VA (1994) Use of enoxaparin, a low-molecular-weight-heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement: a clinical trial comparing efficacy and safety. J Bone Joint Surg Am 76:3–14PubMedGoogle Scholar
Stress Ulcer Prophylaxis
- 266.Misra UK, Kalita J, Pandey S, Mandal SK, Srivastava M (2005) A randomized placebo controlled trial of ranitidine versus sucralfate in patients with spontaneous intracerebral hemorrhage for prevention of gastric hemorrhage. J Neurological Sciences 239:5–10Google Scholar
- 271.Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, Peters S, Rutledge F, Griffith L, McLellan A, Wood G, Kirby A (1998) A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 338:791–797PubMedGoogle Scholar
- 274.Quartin A, Hata JS, Frank WO, Bagin RG, Rock JA, Hepburn B, Laine L (2005) Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 33:760–765PubMedGoogle Scholar
- 276.Selective Decontamination of the Digestive Tract Trialists' Collaborative Group (1993) Meta-analysis of randomised controlled trials of selective decontamination of the digestive tract. BMJ 307:525–532Google Scholar
- 282.Redman R, Ludington E, Crocker M, et al (2001) Analysis of respiratory and non-respiratory infections in published trials of selective digestive decontamination (abstract). Intensive Care Med 27(Suppl 1):S128Google Scholar
- 284.Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L (2004) Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care (Cochrane Review). In: The Cochrane Library, Issue 1. Chichester, UK: Wiley & Sons, Ltd.Google Scholar
- 286.Silvestri L, Milanese M, Durì D, et al. (2005) Impact of SDD on bloodstream infections: a systematic review of randomized trials (abstract). Intensive Care Med 31(Suppl 1):S87Google Scholar
- 287.Hammond JMJ, Potgieter PD (1995) Is there a role for selective decontamination of the digestive tract in primarily infected patients in the ICU? Anaesth Intens Care 23:168–174Google Scholar
- 288.De Jonge E, Schultz M, Spanjaard L, Bossuvt P, Kesecioglu J (2003) Selective decontamination of digestive tract in intensive care. Lancet 362:2119–2120Google Scholar
- 291.de la Cal MA, Cerda E, van Saene HKF, Garcĺa-Hierro P, Negro E, Parra ML, Arias S, Ballesteros D (2004) Effectiveness and safety of enteral vancomycin to control endemicity of methicillin-resistant Staphylococcus aureus in a medical/surgical intensive care unit. J Hospital Infect 56:175–183Google Scholar
Consideration for Limitation of Support
- 294.Curtis JR (2005) Interventions to improve care during withdrawal of life-sustaining treatments. J Palliative Medicine (Suppl 1) 8:S116–31Google Scholar
- 295.Thompson BT, Cox PN, Antonelli M, Carlet JM, Cassell J, Hill NS, Hinds CJ, Pimentel JM, Reinhart K, Thijs LG, American Thoracic Society, European Respiratory Society, European Society of Intensive Care Medicine, Society of Critical Care Medicine, Sociètède Rèanimation de Langue Française (2004) Challenges in end-of-life care in the ICU: statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003: executive summary. Crit Care Med 32:1781–1784PubMedGoogle Scholar
- 301.den Brinker M, Joosten KF, Liem O, de Jong FH, Hop WC, Hazelzet JA, van Dijk M, Hokken-Koelega AC (2005) Adrenal insufficiency in meningococcal sepsis: Bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. Clin Endocrinol Metab 90:5110–5117Google Scholar
- 303.Ngo NT, Cao XT, Kneen R, Wills B, Nguyen VM, Nguyen TQ, Chu VT, Nguyen TT, Simpson JA, Solomon T, White NJ, Farrar J (2001) Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 32:204–213PubMedGoogle Scholar
- 311.Barton P, Garcia J, Kouatli A, Kitchen L, Zorka A, Lindsay C, Lawless S, Giroir B (1996) Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest 109:1302–1312PubMedGoogle Scholar
- 314.Powell KR, Sugarman LI, Eskenazi AE, Woodin KA, Kays MA, McCormick KL, Miller ME, Sladek CD (1991) Normalization of plasma arginine vasopressin concentrations when children with meningitis are given maintenance plus replacement fluid therapy. J Pediatr 117:515–522Google Scholar
- 320.De Kleijn ED, Joosten KF, Van Rijn B, Westerterp M, De Groot R, Hokken-Koelega AC, Hazelzet JA (2002) Low serum cortisol in combination with high adrenocorticotrophic hormone concentrations are associated with poor outcome in children with severe meningococcal disease. Pediatr Infect Dis J 21:330–336PubMedGoogle Scholar
- 323.de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B, Joosten KF, Hazelzet JA (2003) Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 31:1839–1847PubMedGoogle Scholar
- 324.Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B, Researching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group (2007) Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomized controlled trial. Lancet 369:836–843PubMedGoogle Scholar
- 332.Cam PC, Cardone D (2007) Propofol infusion syndrome. Anaesthesia 62:690–701Google Scholar
- 334.Lacroix J, Hébert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, Gauvin F, Collet JP, Toledano BJ, Robillard P, Joffe A, Biarent D, Meert K, Peters MJ, TRIPICU Investigators, Canadian Critical Care Trials Group, Pediatric Acute Lung Injury and Sepsis Investigators Network (2007) Transfusion strategies for patients in pediatric intensive care units. New Engl J Med 256:1609–1619Google Scholar
Summary and Future Directions
- 339.Levy MM, Pronovost PJ, Dellinger RP, Townsend S, Resar RK, Clemmer TP, Ramsay G (2004) Sepsis change bundles: converting guidelines into meaningful change in behavior and clinical outcome. Crit Care Med [Suppl] 32:S595–S597Google Scholar
- 340.Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umberger R (2007) Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest 131:1954–1963Google Scholar
- 341.Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Thompson BT, Ancukiewicz M, National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network (2006) Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 354:1671–1684PubMedGoogle Scholar